Halozyme Therapeutics Approvals for DARZALEX®SC
Halozyme Therapeutics (HALO) announced that the European Commission (EC) has granted Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX® SC in the European Union.
The first authorization relates to the use of DARZALEX® SC in combination with bortezomib . . .